Ultromics' EchoGo® Heart Failure, an artificial intelligence (AI) echocardiography solution, has received FDA approval and may alter the way heart failure with preserved ejection fraction is diagnosed (HFpEF).
One echocardiogram image was used by the device to identify HFpEF, which accounts for half of the 64 million cases of heart failure globally.
HFpEF, a type of heart failure, frequently accompanied by co-morbidities, is typically brought on by a rise in pressure inside the heart's chambers. However, the ejection fraction—the amount of blood that the left ventricle expels with each heartbeat—remains within typical limits.
The signs and symptoms, which include chest pain, shortness of breath, and extreme exhaustion, can significantly affect a person's quality of life. It has a five-year survival rate of just 35% to 40%, is the main cause of hospitalizations, and frequently proves fatal.
HFpEF hasn't historically had a good therapy option. But lately, a new treatment known as sodium-glucose co transporter 2 inhibitors (SGLT2is), which has shown to reduce the relative risk of heart failure hospitalizations by 29%, was given approval.
The most common and highly regarded cardiac imaging technique is echocardiography. It gives quick findings and is safer, more portable, and more affordable than other imaging modalities. The measurement software and instruments that are currently available have drawbacks.
Ultromics advances HFpEF detection by leveraging the strength of AI. By allowing screening, precise diagnosis, and deep phenotyping of HFpEF that directly maps to treatment pathways, the new technology will enhance patient outcomes.
